Preclinical Assets Market Report 2026

The preclinical assets market size has grown strongly in recent years. It will grow from $6.38 billion in 2025 to $7.01 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increasing pharmaceutical r&d investments, expansion of early-stage drug discovery programs, growing reliance on animal-based testing, rising demand for safety data generation, increasing outsourcing of preclinical studies.

The preclinical assets market size is expected to see strong growth in the next few years. It will grow to $10.2 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing adoption of human-relevant preclinical models, rising demand for accelerated drug development timelines, expansion of personalized medicine pipelines, growing integration of ai in preclinical research, increasing regulatory emphasis on data robustness. Major trends in the forecast period include increasing use of advanced preclinical models, growing adoption of patient-derived xenograft and organoid models, rising demand for integrated preclinical services, expansion of safety and toxicology studies, enhanced focus on translational research.

The increasing need to reduce clinical trial expenses is expected to drive the growth of the preclinical assets market in the coming years. Clinical trial costs include the expenditures related to planning, executing, and managing trials that evaluate the safety, effectiveness, and potential benefits of new medical interventions such as drugs, medical devices, or treatment protocols. Preclinical assets play a critical role by generating early insights into safety, efficacy, and possible side effects, helping to assess therapeutic potential before progression to human trials. For instance, in February 2023, according to Genetic Engineering and Biotechnology News, a US-based platform providing updates on genetic engineering and biotechnology, the cost of developing a new drug among the top 20 global biopharmaceutical companies increased by 15%, rising from $298 million in 2022 to approximately $2.3 billion in 2023, which includes expenses incurred during clinical trial development. Therefore, the growing emphasis on controlling clinical trial costs is driving the growth of the preclinical assets market.

Major companies operating in the preclinical assets market are increasingly focusing on strategic collaborations to speed up the discovery and development of novel drug candidates. Such partnerships facilitate the sharing of scientific expertise, access to new therapeutic targets, and the progression of early-stage preclinical assets. For instance, in July 2023, AbbVie, a US-based pharmaceutical company, and Calibr, an India-based research and drug development organization, announced an expanded strategic partnership to continue advancing several innovative preclinical and early-stage clinical assets. This collaboration extends the earlier partnership between AbbVie and Scripps Research. Under the agreement, Calibr will also provide AbbVie with a defined number of new discovery targets and preclinical assets of shared interest for potential option consideration.

In August 2024, Otsuka Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, acquired Jnana Therapeutics Inc. for an undisclosed amount. Through this acquisition, Otsuka gained access to JNT-517, a potential first-in-class oral therapy for phenylketonuria, along with Jnana’s specialty and autoimmune pipeline programs and proprietary drug discovery technologies. Jnana Therapeutics Inc. is a US-based biotechnology company focused on developing early-stage preclinical therapeutic candidates.

Major companies operating in the preclinical assets market are Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore.

North America was the largest region in the preclinical assets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the preclinical assets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the preclinical assets market by increasing costs of imported laboratory equipment, analytical instruments, reagents, animal models, and specialized consumables used in preclinical research. Biopharmaceutical companies and research institutes in North America and Europe are most affected due to reliance on imported scientific equipment, while Asia-Pacific faces higher costs for research supplies. These tariffs can increase study costs and extend development timelines. However, they are also encouraging local manufacturing of laboratory equipment, regional supplier development, and increased investment in domestic preclinical research infrastructure.

The preclinical assets market research report is one of a series of new reports that provides preclinical assets market statistics, including preclinical assets industry global market size, regional shares, competitors with a preclinical assets market share, detailed preclinical assets market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical assets industry. This preclinical assets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A preclinical asset encompasses all clinical trial materials and equipment used during the preclinical development stage, covering activities that bridge laboratory-based drug discovery and the initiation of human clinical trials. This phase occurs prior to human testing and involves critical feasibility studies, repeated evaluations, and the collection of safety data, typically conducted using laboratory animals.

The primary types of preclinical asset services include bioanalysis and drug metabolism and pharmacokinetic (DMPK) studies, toxicology testing, compound management, safety pharmacology, and others. Bioanalysis and DMPK studies are essential elements of the drug development process, concentrating on the evaluation of pharmacokinetic behavior and drug metabolism properties of potential new drug candidates. The models used include patient-derived organoid (PDO) models and patient-derived xenograft models, which are utilized by various end users such as biopharmaceutical companies, government institutes, and others.

The preclinical assets market consists of revenues earned by entities by providing preclinical assets services such as process research and development, asymmetric synthesis, safety pharmacology, and custom synthesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The preclinical assets market consists of sales of chemical compounds, biological samples, and sample storage systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.